How much of Fulgent Genetics'stock is owned by insiders?
Jan 08, 2021 · Shares of Fulgent Genetics ( FLGT 2.23% ), a genetics testing provider, were dropping sharply on Friday and were down by 13.9% as of 11:37 a.m. EST, after falling by as much as 17.3% earlier in ...
Is Fulgent Genetics efficiently growing its dividend?
Aug 27, 2020 · If Abbott's launch is successful, government and corporate clients could shift away from Fulgent Genetics' testing option, causing revenue to drop in future quarters. However, Fulgent Genetics ...
How did Fulgent Genetics'shares rise 93% last year?
Aug 21, 2020 · Year-to-date, Fulgent Genetics Inc. (NASDAQ: FLGT) stock gained 273.1% and on August 20th it had a closing price of $50.51. Here is what Old West Investment Management said: "Fulgent Genetics ...
Will big money lift Fulgent Genetics (flgt) stock in 2021?
Apr 03, 2022 · Earnings for Fulgent Genetics are expected to decrease by -58.82% in the coming year, from $6.29 to $2.59 per share. Price to Earnings Ratio vs. the Market. The P/E ratio of Fulgent Genetics is 3.49, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 12.13. Price to Earnings Ratio vs. Sector
Will fulgent Genetics stock go up?
Fulgent Genetics Inc (NASDAQ:FLGT) The 2 analysts offering 12-month price forecasts for Fulgent Genetics Inc have a median target of 104.00, with a high estimate of 123.00 and a low estimate of 85.00. The median estimate represents a +66.45% increase from the last price of 62.48.
Is fulgent Genetics a buy?
Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy.Feb 9, 2022
Is Fulgent undervalued?
Fulgent, with its brilliant founder, strong insider ownership, plummeting EV, and high growth core business, is undervalued.Dec 20, 2021
Is LMND a buy or sell?
Out of 8 analysts, 1 (12.5%) are recommending LMND as a Strong Buy, 2 (25%) are recommending LMND as a Buy, 3 (37.5%) are recommending LMND as a Hold, 2 (25%) are recommending LMND as a Sell, and 0 (0%) are recommending LMND as a Strong Sell. What is LMND's earnings growth forecast for 2022-2024?
Is Fulgent Genetics a buy right now?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rat...
How has Fulgent Genetics' stock price been impacted by Coronavirus?
Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organizati...
When is Fulgent Genetics' next earnings date?
Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Thursday, May 5th 2022. View our earnings forecast for Fulgen...
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics, Inc. (NASDAQ:FLGT) posted its quarterly earnings results on Wednesday, February, 23rd. The company reported $3.48 earnings per sh...
What guidance has Fulgent Genetics issued on next quarter's earnings?
Fulgent Genetics updated its FY 2022 earnings guidance on Wednesday, March, 16th. The company provided earnings per share guidance of $7.000-$7.000...
What price target have analysts set for FLGT?
2 brokerages have issued twelve-month price objectives for Fulgent Genetics' shares. Their forecasts range from $65.00 to $125.00. On average, they...
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the following people: Ming Hsieh , Chairman, President & Chief Executive Officer James Xie , Chief Op...
Who are some of Fulgent Genetics' key competitors?
Some companies that are related to Fulgent Genetics include Guardant Health (GH) , Natera (NTRA) , Elekta AB (publ) (EKTAY) , Veracyte (VCYT) ,...
What other stocks do shareholders of Fulgent Genetics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Fulgent Genetics investors own include NVIDIA (NVDA) , CR...
Abbott's announcement of a new 15-minute COVID-19 test threatens recent revenue growth
What happened
Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn. Follow @ebcapital
So what
After competitor Abbott Labs ( NYSE:ABT) unveiled a $5, 15-minute COVID-19 test, shares of Fulgent Genetics ( NASDAQ:FLGT) are tumbling 28.7% at 11:15 a.m. EDT on Thursday.
Now what
Fulgent Genetics' bread-and-butter business is providing genetic testing for cancer patients and would-be parents. However, management pivoted earlier this year to provide COVID-19 testing, too, and that's caused revenue and the company's share price to soar.
Is Fulgent Genetics a buy right now?
A faster, cheaper testing alternative could reduce the spread of COVID-19 and help businesses return to normal operations. However, a previous Abbott Labs test drew criticism over potential false positives, so investors will want to wait and see how the test performs following its launch.
What stocks does MarketBeat like better than Fulgent Genetics?
5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Fulgent Genetics stock.
Are investors shorting Fulgent Genetics?
Wall Street analysts have given Fulgent Genetics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Fulgent Genetics wasn't one of them.
When is Fulgent Genetics' next earnings date?
Fulgent Genetics saw a drop in short interest in August. As of August 13th, there was short interest totaling 3,850,000 shares, a drop of 14.3% from the July 29th total of 4,490,000 shares. Based on an average daily trading volume, of 754,000 shares, the days-to-cover ratio is presently 5.1 days.
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.#N#View our earnings forecast for Fulgent Genetics.
How has Fulgent Genetics' stock price been impacted by Coronavirus (COVID-19)?
Fulgent Genetics, Inc. (NASDAQ:FLGT) announced its earnings results on Monday, August, 9th. The company reported $2.47 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.54 by $0.07. The firm earned $153.60 million during the quarter, compared to analysts' expectations of $197.34 million.
What guidance has Fulgent Genetics issued on next quarter's earnings?
Fulgent Genetics' stock was trading at $10.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, FLGT shares have increased by 847.6% and is now trading at $95.33.#N#View which stocks have been most impacted by COVID-19.
Are Robust Financials Driving The Recent Rally In Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Stock?
Fulgent Genetics updated its third quarter 2021 earnings guidance on Monday, September, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $125 million-$150 million, compared to the consensus revenue estimate of $146.10 million.
Why Shares of Fulgent Genetics Are Plunging Today
Fulgent Genetics' (NASDAQ:FLGT) stock is up by a considerable 41% over the past three months. Given the company's...
Fulgent Genetics Reports Second Quarter Financial Results
Shares of coronavirus testing company Fulgent Genetics (NASDAQ: FLGT) are down 16.2% to $91.98 apiece as of 10:30 a.m. EDT. Fulgent derives the overwhelming majority of its revenue from coronavirus testing.
Fulgent Genetics Announces Acquisition of CSI Laboratories
TEMPLE CITY, Calif., August 09, 2021--Fulgent Genetics, Inc. (NASDAQ: FLGT) ("Fulgent" or the "company"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced financial results for its second quarter ended June 30, 2021.
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests
TEMPLE CITY, Calif., August 09, 2021--Fulgent Genetics, Inc.
What's in Store for Fulgent Genetics (FLGT) in Q2 Earnings?
TEMPLE CITY, Calif. & IRVINE, Calif., August 09, 2021--Fulgent Genetics, Inc.
2 Stocks that Could be the Next GME or AMC
Fulgent Genetics' (FLGT) Q2 results are likely to reflect growth in areas like adult neurogenetics, hereditary cancer, hereditary cardiovascular genetics, reproductive health and sequencing as a service.
What is Fulgent Genetics?
Loaded Rifle Investing Think back to early 2020 — a time when r/WallStreetBets was still a dark corner of the internet and the word “Robinhood” conjured images of line-dancing men in a Mel Brooks spoof.
The History of Fulgent Genetics
Genetic testing is somewhat new in the grand scheme of medical science and study, but it’s opened the door to many discoveries and increased the ability to diagnose conditions and even the likelihood of developing certain conditions. People are even doing genetic testing to find out more about their heritage and backgrounds.
Fulgent Genetics Financial History
Fulgent Genetics was founded in 2011 in Temple City, CA by Ming Hsieh, a Chinese born American entrepreneur. The priority of the laboratory was on therapeutic medicine. This focus expanded when Dr Hanlin Gao, who also goes by Harry, joined the team the following year and Fulgent Genetics began to develop diagnostic genetic testing.
Earnings Explain the Rise
While Fulgent Genetics has seen a sharp rise due to the demand for Covid-19 testing, some worry that this will only hurt the company in the long run.
Fulgent Genetics Stock Looking Forward
It’s worth repeating; there is logic to the exponential rise in FLGT stock. All an investor has to do is look at the company’s results.
Room to Run
What we see from Fulgent in the results from the first half of the year is exactly what growth investors should be looking for.
When did Fulgent get emergency use authorization?
Fulgent Genetics stock does not look cheap. It trades at 24x trailing 12-month revenue, and about 150x adjusted earnings per share over the same period.
Is Fulgent Genetics in expansion mode?
May 18 was a big day for Fulgent Genetics. That’s when the company announced that its subsidiary, Fulgent Therapeutics, had received Emergency Use Authorization from the U.S. Food and Drug Administration for its flagship RT-PCR Covid-19 test.
Is Fulgent Genetics FDA approved?
All in all, there’s no doubt that Fulgent Genetics is in expansion mode. The company seems to be making all the right moves, but the valuation of Fulgent Genetics stock might raise eyebrows.